Dr. Lanasa is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2100 Erwin Rd
Durham, NC 27705Phone+1 919-684-8964Fax+1 919-684-5325
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2005 - 2008- Duke University HospitalResidency, Internal Medicine, 2002 - 2005
University of Pittsburgh School of MedicineClass of 2002
Certifications & Licensure
MD State Medical License 2017 - 2019
NC State Medical License 2005 - 2014
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia Start of enrollment: 2007 May 10
- Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM Start of enrollment: 2008 Jun 19
- Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2010 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 16 citationsNatural history of monoclonal B-cell lymphocytosis among relatives in CLL families.Susan L. Slager, Mark C. Lanasa, Gerald E. Marti, Sara J. Achenbach, Nicola J. Camp
Blood. 2021-04-15 - 57 citationsPhase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200Daruka Mahadevan, Mark C. Lanasa, Charles M. Farber, Manjari Pandey, Maria Whelden
Journal for Immunotherapy of Cancer. 2019-08-23 - 70 citationsActionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.Alexandra Schrader, Giuliano Crispatzu, Sebastian Oberbeck, Petra Mayer, S. Pützer
Nature Communications. 2018-02-15
Press Mentions
European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction CancerNovember 27th, 2024- BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell CarcinomaOctober 21st, 2024
- FDA Approves 16 New Cancer Treatments as Global Cancer Rates SkyrocketOctober 4th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
